Abstract
AbstractThe rapid qualitative assessment of surface markers on cancer cells can allow for point-of-care prediction of patient response to various cancer drugs. Preclinical studies targeting cells with an antibody to “activated” matriptase conjugated to a potent toxin show promise as a selective treatment for a variety of solid tumors. In this paper, we implemented a novel technique for electrical detection of proteins on surfaces of cancer cells using multi-frequency microfluidic impedance cytometry. The biosensor, consists of two gold microelectrodes on a glass substrate embedded in a PDMS microfluidic channel, is used in conjugation with immuno-magnetic separation of cancer cells, and is capable of differentiating between bare magnetic beads, cancer cells and bead-cell aggregates based on their various impedance and frequency responses. We demonstrated proof-of-concept based on detection of “activated” matriptase proteins on the surface of cultured Mantle cells.
Funder
Pharmaceutical Research and Manufacturers of America Foundation
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Lin, S.-Y., Bertino, J. R., Lin, C.-Y. & Johnson, M. US Patent 9549993 (2017).
2. Bertino, J. R., Lin, S.-Y. & Lin, C.-Y. In Proceedings of the 101st Annual Meeting of the American Association for Cancer Research AACR. 2596–2596 (AACR) (2010).
3. Lee, S.-L., Dickson, R. B. & Lin, C.-Y. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 275, 36720–36725 (2000).
4. Oberst, M. D. et al. Characterization of matriptase expression in normal human tissues. J. Histochem. Cytochem. 51, 1017–1025 (2003).
5. Kilpatrick, L. M. et al. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood 108, 2616–2623 (2006).
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献